Clinical Trials

Toll-Free: 866.320.4573

Call Us Toll Free:

866.223.2273 x1234

Clinical Trial of PXD101 in Patients With T-Cell Lymphomas

Study:

A Phase II Clinical Trial of PXD101 in Patients With Recurrent or Refractory Cutaneous and Peripheral T-Cell Lymphomas

Rationale:

n/a

Purpose:

This is an open-label, non-randomized trial to assess the effectiveness of PXD101 in patients with recurrent or refractory cutaneous or peripheral and other types of T-cell lymphomas. PXD101 is a new, potent histone deacetylase (HDAC) inhibitor. Patients are treated with belinostat(PXD101) 1000 mg/m2 on days 1-5 of a 21 day cycle.

Study Status: Completed

Recruiting:
n/a

Condition Intervention Phase
Cutaneous T-Cell Lymphoma
Peripheral T-Cell Lymphoma
Non-Hodgkin`s Lymphoma
Drug: belinostat Phase 2

Verified by TopoTarget A/S November, 2013

Sponsored by: TopoTarget A/S
Information provided by: TopoTarget A/S
ClinicalTrials.gov identifier: NCT00274651

Study Type: Interventional

Study Design: Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Cleveland Clinic Foundation
Cleveland, Ohio 44195
United States

n/a

This information is abridged to display results relevant only to Cleveland Clinic. To see complete record visit ClinicalTrials.gov
  Information obtained from ClinicalTrials.gov on
Link to the current ClinicalTrials.gov record.

Cleveland Clinic Mobile Site